Reasons for Levin Capital Strategies – L.P.’s Share Acquisition of Fluidigm (FLDM)’s Stock; Ashford Capital Management Has Decreased Its Ligand Pharmaceuticals (LGND) Stake

Fluidigm Corporation (NASDAQ:FLDM) Logo

Ashford Capital Management Inc decreased Ligand Pharmaceuticals (LGND) stake by 3.43% reported in 2017Q4 SEC filing. Ashford Capital Management Inc sold 4,550 shares as Ligand Pharmaceuticals (LGND)’s stock rose 20.51%. The Ashford Capital Management Inc holds 127,987 shares with $17.53M value, down from 132,537 last quarter. Ligand Pharmaceuticals now has $3.28B valuation. The stock decreased 1.68% or $2.64 during the last trading session, reaching $154.85. About 297,391 shares traded. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) has risen 53.11% since May 1, 2017 and is uptrending. It has outperformed by 41.56% the S&P500.

Fluidigm Corporation (NASDAQ:FLDM) Ratings Coverage

Among 5 analysts covering Fluidigm (NASDAQ:FLDM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Fluidigm has $28 highest and $4.4 lowest target. $12.62’s average target is 113.90% above currents $5.9 stock price. Fluidigm had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating by Cowen & Co given on Friday, August 4. The stock of Fluidigm Corporation (NASDAQ:FLDM) has “Neutral” rating given on Friday, October 30 by Mizuho. The rating was initiated by Cantor Fitzgerald on Wednesday, August 26 with “Hold”. Piper Jaffray downgraded Fluidigm Corporation (NASDAQ:FLDM) rating on Friday, August 7. Piper Jaffray has “Neutral” rating and $15 target. The company was upgraded on Friday, August 21 by Zacks. Piper Jaffray maintained the stock with “Hold” rating in Thursday, August 3 report. The company was maintained on Friday, August 5 by Cantor Fitzgerald. The firm has “Buy” rating by Mizuho given on Friday, August 5. Cowen & Co maintained it with “Hold” rating and $7.25 target in Wednesday, December 20 report. Cowen & Co maintained the stock with “Outperform” rating in Friday, October 2 report.

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. The company has market cap of $228.99 million. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 systems; integrated fluidic circuits consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. It currently has negative earnings. The firm also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules.

Investors sentiment increased to 1.61 in Q4 2017. Its up 0.03, from 1.58 in 2017Q3. It increased, as 9 investors sold Fluidigm Corporation shares while 19 reduced holdings. 15 funds opened positions while 30 raised stakes. 32.56 million shares or 0.48% more from 32.41 million shares in 2017Q3 were reported. Ameritas Invest Ptnrs has 2,221 shares. Blackrock invested 0% in Fluidigm Corporation (NASDAQ:FLDM). Wasatch Advisors has invested 0.02% in Fluidigm Corporation (NASDAQ:FLDM). 61,118 were accumulated by California State Teachers Retirement Sys. Goldman Sachs Gru Inc holds 0% of its portfolio in Fluidigm Corporation (NASDAQ:FLDM) for 205,254 shares. Employees Retirement System Of Ohio holds 0% or 45,664 shares in its portfolio. Legal & General Gp Plc holds 0% or 9,571 shares. Invesco Limited owns 13,181 shares. 26,300 are held by Ny State Common Retirement Fund. Panagora Asset has invested 0.01% in Fluidigm Corporation (NASDAQ:FLDM). Metropolitan Life Company Ny reported 0% stake. Deutsche Bancshares Ag invested in 0% or 138,701 shares. Healthcare Value Cap Limited Liability stated it has 7.35% in Fluidigm Corporation (NASDAQ:FLDM). Moreover, Neuberger Berman Gru Limited Liability Com has 0.03% invested in Fluidigm Corporation (NASDAQ:FLDM) for 4.75 million shares. Rhumbline Advisers accumulated 27,941 shares or 0% of the stock.

Analysts await Fluidigm Corporation (NASDAQ:FLDM) to report earnings on May, 3. They expect $-0.30 EPS, up 26.83% or $0.11 from last year’s $-0.41 per share. After $-0.13 actual EPS reported by Fluidigm Corporation for the previous quarter, Wall Street now forecasts 130.77% negative EPS growth.

Since December 11, 2017, it had 19 buys, and 0 insider sales for $4.86 million activity. $45,125 worth of Fluidigm Corporation (NASDAQ:FLDM) was bought by LEVIN CAPITAL STRATEGIES – L.P..

The stock decreased 1.99% or $0.12 during the last trading session, reaching $5.9. About 56,430 shares traded. Fluidigm Corporation (NASDAQ:FLDM) has risen 7.86% since May 1, 2017 and is uptrending. It has underperformed by 3.69% the S&P500.

The shareholder of Fluidigm Corp, Levin Capital Strategies – L.P., also an insider, bought some 9,609 of the Pinksheet-listed company shares having a value near $57,271 U.S Dollars with an average of $6.0 stock price for a share. This deal, which was filled on April 30, 2018 was unveiled in a 4F filing with the Security Exchange Commission. Mr. Levin Capital Strategies – L.P. today holds 12.52 million shares, accounting for 32.25% of the Company’s total market cap.

Ashford Capital Management Inc increased Ishares Core Us Credit Bond (CRED) stake by 6,010 shares to 62,105 valued at $6.96 million in 2017Q4. It also upped Costar Group Inc (NASDAQ:CSGP) stake by 1,109 shares and now owns 35,660 shares. Commvault Systems Inc. (NASDAQ:CVLT) was raised too.

Among 6 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 5 have Buy rating, 1 Sell and 0 Hold. Therefore 83% are positive. Ligand Pharmaceuticals had 29 analyst reports since September 3, 2015 according to SRatingsIntel. H.C. Wainwright maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) rating on Wednesday, January 24. H.C. Wainwright has “Buy” rating and $170 target. As per Thursday, October 5, the company rating was maintained by H.C. Wainwright. Roth Capital maintained the shares of LGND in report on Monday, September 21 with “Buy” rating. The firm has “Buy” rating given on Friday, December 18 by Roth Capital. On Wednesday, October 11 the stock rating was maintained by Roth Capital with “Buy”. TH Capital maintained it with “Buy” rating and $140 target in Wednesday, September 30 report. Craig Hallum maintained Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) on Wednesday, November 15 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Thursday, September 3 report. Stephens initiated the stock with “Overweight” rating in Wednesday, April 13 report. The rating was reinitiated by H.C. Wainwright with “Buy” on Tuesday, September 5.

Investors sentiment decreased to 1.25 in Q4 2017. Its down 0.44, from 1.69 in 2017Q3. It dived, as 21 investors sold LGND shares while 86 reduced holdings. 31 funds opened positions while 103 raised stakes. 22.68 million shares or 0.37% less from 22.76 million shares in 2017Q3 were reported. New York-based Renaissance Ltd Limited Liability Company has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Moreover, Court Place Advisors Ltd Company has 1.13% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Smith Asset Gru Lp invested 0.02% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Woodstock Corporation accumulated 69,148 shares or 1.75% of the stock. 55 were accumulated by Telemus Capital Lc. Bancshares Of Montreal Can holds 0% or 9,922 shares. 1,947 are owned by M&T Comml Bank. Great West Life Assurance Co Can reported 27,817 shares or 0.01% of all its holdings. Baker Bros Advsr Lp has invested 0.09% of its portfolio in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Citigroup, New York-based fund reported 36,347 shares. Campbell Newman Asset has 0.08% invested in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) for 3,495 shares. Congress Asset Ma accumulated 18,631 shares or 0.04% of the stock. Nordea Mngmt, Sweden-based fund reported 18,251 shares. State Street Corp reported 967,527 shares. The New York-based D E Shaw Communications Incorporated has invested 0.01% in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).

Analysts await Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to report earnings on May, 8. They expect $1.11 EPS, up 184.62% or $0.72 from last year’s $0.39 per share. LGND’s profit will be $23.53 million for 34.88 P/E if the $1.11 EPS becomes a reality. After $1.03 actual EPS reported by Ligand Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts 7.77% EPS growth.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Institutional Positions Chart